← Back to Research Watchlist
KNSA
Kiniksa Pharmaceuticals International plc. - Class A
Market Cap
$3.22B
Enterprise Val
$2.81B
P/E Ratio
54.54
P/B Ratio
5.67
Trailing PEG (1Y)
-0.21
As Of
Apr 19, 2026
Overview & Key Metrics
Reporting period: Dec 31, 2025 · Q4 2025
Book Value$567.6M
Gross Margin89.64%
Profit Margin89.64%
Return on Equity11.48%
Return on Assets8.63%
Current Ratio3.79
Debt/Equity0.02
LT Debt/Equity0.01
Revenue Per Share2.67
Income Statement
Dec 31, 2025
Revenue$202.1M
Cost of Revenue$20.9M
Gross Profit$181.2M
R&D$34.6M
SG&A$56.8M
Operating Expenses$161.4M
Operating Income$19.8M
Interest Expense$0.00
Tax Expense$9.1M
Net Income$14.2M
EPS (Basic)$0.19
EPS (Diluted)$0.18
EBIT$23.3M
EBITDA$24.7M
Consolidated Income$14.2M
Non-Controlling Interests$0.00
Balance Sheet
Dec 31, 2025
Cash & Equivalents$165.6M
Accounts Receivable$15.6M
Inventory$54.9M
Current Assets$527.2M
LT Investments$0.00
Property, Plant & Equipment$11.8M
Intangibles$15.3M
Non-Current Assets$236.5M
Total Assets$763.6M
Accounts Payable$2.0M
Current Debt$3.0M
Current Liabilities$139.2M
LT Debt$6.5M
Non-Current Liabilities$56.8M
Total Liabilities$196.0M
Total Debt$9.5M
Retained Earnings-$462.1M
Shareholder Equity$567.6M
Shares Outstanding75,795,759
Cash Flow Statement
Dec 31, 2025
Operating Cash Flow$53.9M
Investing Cash Flow-$70.8M
Financing Cash Flow$7.7M
CapEx-$633.0K
Free Cash Flow$53.3M
Depreciation & Amort.$1.4M
Stock-Based Comp$10.2M
Acquisitions / Disposals$0.00
Investment Activity-$70.2M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$7.7M
Dividends Paid$0.00
Net Change in Cash-$9.3M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h
